BioLineRx (BLRX) Enterprise Value (2015 - 2026)

BioLineRx's Enterprise Value history runs 16 years deep, the most recent figure standing at -$15.7 million for Q4 2025.

• In Q4 2025, Enterprise Value rose 19.6% year-over-year to -$15.7 million; the TTM figure through Dec 2025 stood at -$15.7 million (up 19.6% YoY), while the FY2025 annual figure was -$15.7 million, up 19.6% from the prior year.
• Enterprise Value for Q4 2025 stood at -$15.7 million, up from -$25.2 million in the prior quarter.
• The five-year high for Enterprise Value was -$15.7 million in Q4 2025, with the low at -$65.6 million in Q2 2021.
• The 5-year median for Enterprise Value is -$41.5 million (2023), against an average of -$40.1 million.
• The sharpest annual moves came in 2021 and 2023: Enterprise Value slumped 198.67% in 2021, then soared 54.65% in 2023.
• BioLineRx's Enterprise Value stood at -$57.1 million in 2021, then rose by 10.59% to -$51.1 million in 2022, then advanced by 15.83% to -$43.0 million in 2023, then jumped by 54.5% to -$19.6 million in 2024, then increased by 19.6% to -$15.7 million in 2025.
• Business Quant data shows BLRX's Enterprise Value at -$15.7 million in Q4 2025, -$25.2 million in Q3 2025, and -$28.2 million in Q2 2025.